We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Messenger RNA (mRNA) therapeutics hold significant promise for the future of personalized cancer treatment, but persistent off-target effects and treatment-resistant tumour microenvironments have limited progress.